Investigator

Dogan Uncu

Ankara Bilkent City Hospital

DUDogan Uncu
Papers(2)
Thiol-disulfide homeo…Defining the relation…
Collaborators(10)
Enes Seyda SahinerFatih KilicFatma OzmenFirat OrtacGökşen GörgülüGokhan UcarGunsu Kimyon ComertHande Esra Koca Yildi…Ilker SelcukIsin Ureyen
Institutions(6)
Ankara Bilkent City H…Adana HospitalAnkara UniversityIzmir UniversityAnkara Etlik City Hos…Mraniye Eitim Ve Arat…

Papers

Thiol-disulfide homeostasis and ischemia modified albumin levels in patients diagnosed with ovary carcinoma

Abstract In our study, we determined the changes in the oxidative stress (OxS) biomarkers, thiol-disulfide (TD) homeostasis and ischemia-modified albumin (IMA) levels, in patients diagnosed with ovarian carcinoma before and after chemotherapy. We will examine the indirect effects of chemotherapy on OxS and antioxidant capacity by measuring changes in these blood biomarkers and compare the results with those of the healthy control group. This case–control study, which was conducted in a single-center, prospective design, included 42 patients diagnosed with ovarian cancer and 51 healthy volunteers. Venous blood samples were taken from all participants after 8 h of fasting, their serum was separated, and the serum total thiol, native thiol, disulfide, and IMA values were measured. In the comparison of the blood samples taken before the chemotherapy treatment of the patient group with the healthy control group, the native thiol (p < 0.001), total thiol (p < 0.001), and native thiol/total thiol (p < 0.001) values were found to be statistically significantly lower, and the disulfide (p = 0.001), disulfide/native (p < 0.001), and disulfide/total thiol (p < 0.001) levels were found to be statistically significantly greater. In the patient group diagnosed with ovarian cancer, a statistically significant difference was detected between the measurements of cancer antigen-125 (CA-125) (p < 0.001), native thiol (p = 0.019), and total thiol (p = 0.025) values at the 0th month before chemotherapy treatment and the third month after chemotherapy treatment. In the group that received adjuvant chemotherapy after the operation, the native thiol (p = 0.035), total thiol (p = 0.043), disulfide/native thiol (p = 0.035), disulfide total thiol (p = 0.035), native thiol/total thiol (p = 0.035) and IMA (p = 0.026) values were statistically significantly different between the diagnosis and third-month values. Our study suggests that TD homeostasis may be an important guide in terms of disease progression, complications during chemotherapy treatment, appropriate dose reductions, and modifications in chemotherapy depending on the toxicities experienced and the goals of the treatment.

Defining the relationship between ovarian adult granulosa cell tumors and synchronous endometrial pathology: Does ovarian tumor size correlate with endometrial cancer?

Abstract Objective The main feature of adult granulosa cell tumors (AGCT) is their capacity to secrete hormones, with nearly all of them capable of synthesizing oestradiol. The primary goal of this study is to identify synchronized endometrial pathologies, particularly endometrial cancer, in AGCT patients who had undergone a hysterectomy. Materials and Methods The study cohort comprised retrospectively of 316 AGCT patients from 10 tertiary gynecological oncology centers. AGCT surgery consisted of bilateral salpingo‐oophorectomy, hysterectomy, peritoneal cytology, omentectomy, and the excision of any suspicious lesion. The median tumor size value was used to define the relationship between tumor size and endometrial cancer. The relationship between each value and endometrial cancer was evaluated. Results Endometrial intraepithelial neoplasia, or hyperplasia with complex atypia, was detected in 7.3% of patients, and endometrial cancer in 3.1% of patients. Age, menopausal status, tumor size, International Federation of Gynecology and Obstetrics stage, ascites, and CA‐125 level were not statistically significant factors to predict endometrial cancer. There was no endometrial cancer under the age of 40, and 97.8% of women diagnosed with endometrial hyperplasia were over the age of 40. During the menopausal period, the endometrial cancer risk was 4.5%. Developing endometrial cancer increased to 12.1% from 3.2% when the size of the tumor was >150 mm in menopausal patients ( p  = 0.036). Conclusion Endometrial hyperplasia, or cancer, occurs in approximately 30% of AGCT patients. Patients diagnosed with AGCT, especially those older than 40 years, should be evaluated for endometrial pathologies. There may be a relationship between tumor size and endometrial cancer, especially in menopausal patients.

9Works
2Papers
42Collaborators
PrognosisStomach NeoplasmsOvarian NeoplasmsBiomarkers, TumorColorectal NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic NeoplasmsBreast Neoplasms